Bicara Therapeutics names Jeremy Bender, Christy Oliger to board

• Bicara Therapeutics appointed Jeremy Bender, Ph.D., MBA and Christy Oliger to its board.
• Bender was CEO of Day One Biopharmaceuticals through its 2026 acquisition by Servier; he has more than 20 years of biotech strategy experience.
• Oliger most recently served as senior vice president of Genentech’s Oncology Business Unit; she has more than 30 years of commercial experience.
• Founding board member Kiran Mazumdar-Shaw retired from the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280830PRIMZONEFULLFEED9798971) on July 28, 2026, and is solely responsible for the information contained therein.